ArticleMMWR. Morbidity and mortality weekly report2020
Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020.
Article in MMWR. Morbidity and mortality weekly report, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 204 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
204 citing papers in PubMed, 4 syntheses or guidelines pooled it, 412 citations in OpenAlex.
- Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.The Journal of infectious diseases · 2025Pooled it
- Antimicrobial resistance of Neisseria gonorrhoeae in Latin American countries: a systematic review.The Journal of antimicrobial chemotherapy · 2023Pooled it
- Pooled it
- Sexually Transmitted Infections Treatment Guidelines, 2021.MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports · 2021Guideline
- Effect of food on the pharmacokinetics of zoliflodacin granules for oral suspension: Phase I open-label randomized cross-over study in healthy subjects.Clinical and translational science · 2023Trial
- Thorough QT Study To Evaluate the Effect of Zoliflodacin, a Novel Therapeutic for Gonorrhea, on Cardiac Repolarization in Healthy Adults.Antimicrobial agents and chemotherapy · 2021Trial
- Measuring the health benefits and costs of antimicrobial-resistant gonorrhea surveillance in the United States: an agent-based model and cost-effectiveness analysis.Lancet regional health. Americas · 2026Article
- A Standards-Based, Cloud-Hosted CDS System for Gonorrhea Treatment and HIV Screening.Learning health systems · 2026Article
- Heterogeneity of azithromycin resistance markers inNew microbes and new infections · 2026Review
- Genomic analysis ofMicrobiology spectrum · 2026Article
- Antimicrobial resistance in Neisseria gonorrhoeae isolates at the Bangrak STIs Center, Bangkok, Thailand and WGS of antimicrobial-resistant isolates, 2018-23.The Journal of antimicrobial chemotherapy · 2026Article
- Antimicrobial Resistance in Extragenital Neisseria gonorrhoeae Infections, US Military Centers, 2022-2024.Emerging infectious diseases · 2026Article
- Impact of Changes in Chlamydia Treatment Guidelines on Recurrent/Persistent RectalOpen forum infectious diseases · 2026Article
- An mRNA-Lipid Nanoparticle Platform Encoding the Conserved Outer Membrane Protein BamA Elicits Broadly Cross-Reactive Systemic and Mucosal Antibodies Against Antimicrobial-ResistantbioRxiv : the preprint server for biology · 2026Article
- Aerocavin Is an Antibiotic with Potent and Specific Anti-Neisserial Activity.ACS infectious diseases · 2026Article
- Pharyngeal gonorrhea in Ugandan men with urogenital gonorrhea: differences in antimicrobial resistance and strain types between anatomical sites.The Journal of infectious diseases · 2026Article
- The Path of Estimated Resistance: Updates of the Estimated Number and Cost of Antimicrobial-Resistant Gonococcal Infections in Men and Women Aged 15 to 39 Years in the United States: 2018-2023.Sexually transmitted diseases · 2026Article
- Plasmids inClinical microbiology reviews · 2026Review
- Mapping antibiotic treatment failure definitions and criteria in ambulatory care: a systematic literature review.JAC-antimicrobial resistance · 2026Review
- Inferring Sexual Network Bridging Using Genomics: A Simulation Study.medRxiv : the preprint server for health sciences · 2026Article
144 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sexually transmitted infections (STIs) caused by the bacteria Neisseria gonorrhoeae (gonococcal infections) have increased 63% since 2014 and are a cause of sequelae including pelvic inflammatory disease, ectopic pregnancy, and infertility and can facilitate transmission of human immunodeficiency virus (HIV) (1,2). Effective treatment can prevent complications and transmission, but N. gonorrhoeae's ability to acquire antimicrobial resistance influences treatment recommendations and complicates control (3). In 2010, CDC recommended a single 250 mg intramuscular (IM) dose of ceftriaxone and a single 1 g oral dose of azithromycin for treatment of uncomplicated gonococcal infections of the cervix, urethra, and rectum as a strategy for preventing ceftriaxone resistance and treating possible coinfection with Chlamydia trachomatis (4). Increasing concern for antimicrobial stewardship and the potential impact of dual therapy on commensal organisms and concurrent pathogens (3), in conjunction with the continued low incidence of ceftriaxone resistance and the increased incidence of azithromycin resistance, has led to reevaluation of this recommendation. This report, which updates previous guidelines (5), recommends a single 500 mg IM dose of ceftriaxone for treatment of uncomplicated urogenital, anorectal, and pharyngeal gonorrhea. If chlamydial infection has not been excluded, concurrent treatment with doxycycline (100 mg orally twice a day for 7 days) is recommended. Continuing to monitor for emergence of ceftriaxone resistance through surveillance and health care providers' reporting of treatment failures is essential to ensuring continued efficacy of recommended regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.